HOWL Valuation

Werewolf Therapeutics Inc

Add to Watchlist

Advanced Chart

1.340

+0.01(0.752%)1D

Overview
Forecast
Valuation
Earnings

HOWL Relative Valuation

HOWL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HOWL is overvalued; if below, it's undervalued.

Historical Valuation

Werewolf Therapeutics Inc (HOWL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -3.20. The fair price of Werewolf Therapeutics Inc (HOWL) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 1.34 USD , Werewolf Therapeutics Inc is Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：1.34

Fair

Undervalued

-0.79

Trailing

Forward

-0.25

EV/EBITDA

Werewolf Therapeutics Inc. (HOWL) has a current EV/EBITDA of -0.25. The 5-year average EV/EBITDA is -0.94. The thresholds are as follows: Strongly Undervalued below -5.95, Undervalued between -5.95 and -3.45, Fairly Valued between 1.57 and -3.45, Overvalued between 1.57 and 4.07, and Strongly Overvalued above 4.07. The current Forward EV/EBITDA of -0.25 falls within the Historic Trend Line -Fairly Valued range.

-0.24

EV/EBIT

Werewolf Therapeutics Inc. (HOWL) has a current EV/EBIT of -0.24. The 5-year average EV/EBIT is -1.55. The thresholds are as follows: Strongly Undervalued below -9.02, Undervalued between -9.02 and -5.28, Fairly Valued between 2.18 and -5.28, Overvalued between 2.18 and 5.92, and Strongly Overvalued above 5.92. The current Forward EV/EBIT of -0.24 falls within the Historic Trend Line -Fairly Valued range.

0.00

Werewolf Therapeutics Inc. (HOWL) has a current PS of 0.00. The 5-year average PS is 23.21. The thresholds are as follows: Strongly Undervalued below -29.06, Undervalued between -29.06 and -2.93, Fairly Valued between 49.34 and -2.93, Overvalued between 49.34 and 75.48, and Strongly Overvalued above 75.48. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.79

P/OCF

Werewolf Therapeutics Inc. (HOWL) has a current P/OCF of -0.79. The 5-year average P/OCF is -2.22. The thresholds are as follows: Strongly Undervalued below -8.06, Undervalued between -8.06 and -5.14, Fairly Valued between 0.70 and -5.14, Overvalued between 0.70 and 3.62, and Strongly Overvalued above 3.62. The current Forward P/OCF of -0.79 falls within the Historic Trend Line -Fairly Valued range.

-1.02

P/FCF

Werewolf Therapeutics Inc. (HOWL) has a current P/FCF of -1.02. The 5-year average P/FCF is -2.99. The thresholds are as follows: Strongly Undervalued below -7.72, Undervalued between -7.72 and -5.35, Fairly Valued between -0.62 and -5.35, Overvalued between -0.62 and 1.74, and Strongly Overvalued above 1.74. The current Forward P/FCF of -1.02 falls within the Historic Trend Line -Fairly Valued range.

Werewolf Therapeutics Inc (HOWL) has a current Price-to-Book (P/B) ratio of 1.45. Compared to its 3-year average P/B ratio of 1.01 , the current P/B ratio is approximately 43.40% higher. Relative to its 5-year average P/B ratio of 1.16, the current P/B ratio is about 25.18% higher. Werewolf Therapeutics Inc (HOWL) has a Forward Free Cash Flow (FCF) yield of approximately -102.90%. Compared to its 3-year average FCF yield of -55.20%, the current FCF yield is approximately 86.42% lower. Relative to its 5-year average FCF yield of -44.11% , the current FCF yield is about 133.29% lower.

1.45

P/B

Median3y

1.01

Median5y

1.16

-102.90

FCF Yield

Median3y

-55.20

Median5y

-44.11

Competitors Valuation Multiple

The average P/S ratio for HOWL's competitors is 10.68, providing a benchmark for relative valuation. Werewolf Therapeutics Inc Corp (HOWL) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

HOWL.O

Werewolf Therapeutics Inc

Adverum Biotechnologies Inc

Plus Therapeutics Inc

Performance Decomposition

Market capitalization of HOWL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of HOWL in the past 1 year is driven by Unknown.